Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Presentation of Data Confirming Envisia Genomic Classifier’s Ability to Improve Diagnosis of Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 8, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis
View HTML
Toggle Summary Veracyte Announces that New Data from Multiple Studies Demonstrate “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis
Study findings reported at the American Thyroid Association Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 6, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that new findings from six studies reinforcing the “real world” performance of the next-generation Afirma Genomic
View HTML
Toggle Summary Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 27, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 , at 1:05 p.m.
View HTML
Toggle Summary Veracyte Announces New Data Reinforcing Clinical Value of Genomic Tests In Lung Disease Diagnoses to Be Presented at CHEST Annual Meeting 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 27, 2018-- Veracyte, Inc. (NASDAQ: VCYT) announced that new data highlighting the ability of the Percepta Bronchial Genomic Classifier to reduce unnecessary invasive procedures in lung cancer diagnosis will be shared in an oral presentation at
View HTML
Toggle Summary Veracyte Announces Multiple Studies to Be Presented at ATA Annual Meeting Demonstrating “Real World” Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 26, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from six studies will be presented at the 88 th Annual Meeting of the American Thyroid Association (ATA), demonstrating the “real world” performance of the Afirma Genomic
View HTML
Toggle Summary Veracyte Achieves Major Medicare Milestone for the Envisia Genomic Classifier
First Test for Improved IPF Diagnosis Receives Draft Local Coverage Determination Through the MolDx Program SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that it has received a draft Medicare local coverage determination (LCD) for the Envisia
View HTML
Toggle Summary Veracyte to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 2:55 p.m.
View HTML
Toggle Summary Veracyte Names Angeline McCabe as Vice President, Investor Relations and Corporate Communications
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 29, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that the company has named Angeline (“Angie”) McCabe as vice president, investor relations and corporate communications, effective immediately. In this role, Ms.
View HTML
Toggle Summary Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 11:30 a.m.
View HTML
Toggle Summary Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 5,750,000 shares of common stock, including 750,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
View HTML